Written Treatment Plan Versus Usual Care for Treating Individuals With Asthma
Information source: National Heart, Lung, and Blood Institute (NHLBI)
Information obtained from ClinicalTrials.gov on November 03, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Written Treatment Plan (Behavioral)
Phase: N/A
Status: Recruiting
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI) Official(s) and/or principal investigator(s): David Evans, PhD, Principal Investigator, Affiliation: Columbia University
Overall contact: David Evans, PhD, Phone: 212-305-6732, Email: de8@columbia.edu
Summary
The overall goal of this randomized, controlled study is to compare a model written treatment
plan with the usual care that is provided by a group of adult and pediatric pulmonologists
and allergists in their practice settings. The written treatment plan is a form that allows a
treatment regimen that is consistent with National Heart, Lung, and Blood Institute (NHLBI)
guidelines to be conveyed to patients. Barriers to the use of written plans will be
identified to better understand why some patients and physicians use written treatment plans
more frequently and effectively than others. An additional goal is to assess how patients
from different racial/ethnic backgrounds utilize treatments plans. Because asthma
disproportionately affects African American and Latino patients, another goal of this study
is to better understand if there are fundamental differences in the way patients from
racial/ethnic minority groups self-manage asthma in comparison to their white counterparts.
The study will also try to determine if differences exist in the way physicians care for
minority patients. If there are differences, it is important to determine if the disparities
can be overcome with the use of a written treatment plan form.
Clinical Details
Official title: The Efficacy of Written Treatment Plans in Asthma
Study design: Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study
Primary outcome: Reduction in asthma symptom frequencyReduction in urgent, unscheduled, and emergency visits for asthma Improved quality of life
Secondary outcome: Hospitalizations due to asthmaDays with activity restriction Proportion of patients in the intervention group who are given the model written plan form during the initial visit Proportion of patients in the intervention group who have the model treatment plan at the end of the follow-up period
Detailed description:
BACKGROUND:
Effective self-management of asthma requires that patients, or their caregivers, recognize
the early symptoms of an exacerbation and initiate appropriate interventions aimed at
preventing the progression of symptoms. Most asthma clinical guidelines suggest that the
incorporation of a written self-management plan is essential. Patients must possess,
understand, and follow a written plan if they are to respond appropriately to changes in
asthma status. Nevertheless, there are no controlled studies examining the efficacy of the
written plan itself. Furthermore, even if written plans are an essential and effective
component of successful self-management, the data suggest that few patients receive these
plans. If patients and physicians are to increase their use of written plans, the barriers to
the use of these plans need further investigation.
DESIGN NARRATIVE:
The three primary outcome measures of this study are as follows: 1) reduction in asthma
symptom frequency; 2) reduction in urgent, unscheduled, and emergency visits for asthma; and
3) improved quality of life. These outcomes will be measured over a 12-month period.
The following four secondary outcome measures will also be examined: 1) hospitalizations due
to asthma; 2) days with activity restriction; 3) the proportion of patients in the
intervention group who are given the model written plan form during the initial visit; and 4)
the proportion of patients in the intervention group who have the model treatment plan at the
end of the follow-up period. These outcomes will be measured over a 12-month period.
Eligibility
Minimum age: 3 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- This study will enroll parents of children (ages 3-17 years) with asthma and adult
patients with asthma (ages 18-75 years) whe receive care at one of 3 centers (New York
Presbyterian Hospital-Columbia campus, New York Presbyterian Hospital-Cornell campus,
and Harlem Hospital Center)
- Diagnosis of persistent asthma (as defined by NHLBI guidelines)
- Diagnosis of asthma was made using commonly accepted clinical criteria (episodic
symptoms of airflow obstruction, airflow obstruction that is at least partially
reversible, and reasonable alternative diagnoses have been excluded)
- Evidence of at least mild persistent asthma, based on the finding of at least one of
the following clinical features before treatment:
1. Presence of symptoms (3 or more days a week)
2. Nocturnal asthma symptoms (3 or more times a month)
3. PEF variability of at least 20% to 30%
Exclusion Criteria:
- Co-morbidity with conditions that affect lung function (e. g, congenital or acquired
heart disease, neuromuscular disease, sickle cell disease, or chronic lung disease
[bronchopulmonary dysplasia, emphysema, or cystic fibrosis])
Locations and Contacts
David Evans, PhD, Phone: 212-305-6732, Email: de8@columbia.edu
Columbia University, New York, New York 10032, United States; Recruiting Beverley J. Sheares, MD, MS, Email: bjs4@columbia.edu David Evans, PhD, Principal Investigator
Additional Information
Starting date: August 2003
Ending date: August 2009
Last updated: January 31, 2008
|